Comments on Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small-Cell Lung Cancer after Progression during First-Line EGFR Tyrosine Kinase Inhibitor Therapy

被引：3

作者：

Hoyle, Christopher ^{[1
]}

Dyer, Matthew ^{[1
]}

机构：

[1] AstraZeneca, Acad House,136 Hills Rd, Cambridge CB2 8PA, Cambs, England

来源：

JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 05期

关键词：

D O I：

10.1016/j.jtho.2018.02.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：E83 / E84

页数：2

共 50 条

[31] COST-EFFECTIVENESS OF DACOMITINIB VS. GEFITINIB AS FIRST-LINE TREATMENT FOR EGFR MUTATION POSITIVE ADVANCED NON-SMALL-CELL LUNG CANCER IN CHINA [J].

Yu, Y. ;

Luan, L. ;

Zhu, F. ;

Dong, P. ;

Li, L. ;

Lin, Y. ;

Lu, S. .

VALUE IN HEALTH, 2019, 22 :S467-S468

[32] Patterns of progression on first-line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study [J].

Schuler, A. ;

Huser, J. ;

Schaer, S. ;

Schmid, S. ;

Scherz, A. ;

Gautschi, O. ;

Mauti, L. A. ;

Von Briel, T. ;

Waibel, C. ;

De Nicola, L. Wannesson ;

Pankovics, J. ;

Mark, M. T. ;

Rothschild, S. I. ;

Addeo, A. ;

Janthur, W-D. ;

Siano, M. ;

Britschgi, C. ;

Frueh, M. .

ANNALS OF ONCOLOGY, 2022, 33 :S1584-S1585

[33] First-line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation-positive non-small cell lung cancer [J].

Su, Po-Lan ;

Chen, Chian-Wei ;

Wu, Yi-Lin ;

Lin, Chien-Chung ;

Su, Wu-Chou .

THORACIC CANCER, 2021, 12 (03) :287-296

[34] Dynamic changes in quality of life after three first-line therapies for EGFR mutation-positive advanced non-small-cell lung cancer [J].

Yang, Szu-Chun ;

Lin, Chien-Chung ;

Lai, Wu-Wei ;

Chang, Sheng-Mao ;

Hwang, Jing-Shiang ;

Su, Wu-Chou ;

Wang, Jung-Der .

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10

[35] Osimertinib as First-Line Treatment in EGFR-Mutated Non-Small-Cell Lung Cancer [J].

Popat, Sanjay .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (02) :192-193

[36] Osimertinib as first-line treatment of EGFR mutant advanced non-small-cell lung cancer [J].

Liam, Chong-Kin .

TRANSLATIONAL LUNG CANCER RESEARCH, 2017, 6 :S62-S66

[37] First-line treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) by gefitinib [J].

Moiseyenko, V. ;

Procenko, S. A. ;

Levchenko, E. V. ;

Barchuk, A. S. ;

Matsko, D. E. ;

Moiseyenko, F. V. ;

Ivantsov, A. O. ;

Iyevleva, A. G. ;

Mitiushkina, N. V. ;

Imyanitov, E. N. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)

[38] Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States [J].

Ting, Jie ;

Ho, Tien ;

Xiang, Pin ;

Sugay, Amanda ;

Abdel-Sattar, Maher ;

Wilson, Leslie .

VALUE IN HEALTH, 2015, 18 (06) :774-782

[39] The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer [J].

Bai, Hao ;

Xiong, Liwen ;

Han, Baohui .

ONCOTARGETS AND THERAPY, 2017, 10 :2335-2340

[40] Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer [J].

Park, Keunchil ;

Bennouna, Jaafar ;

Boyer, Michael ;

Hida, Toyoaki ;

Hirsh, Vera ;

Kato, Terufumi ;

Lug, Shun ;

Mok, Tony ;

Nakagawa, Kazuhiko ;

O'Byrne, Kenneth ;

Paz-Ares, Luis ;

Schuler, Martin ;

Sibilotru, Denis Moro ;

Tan, Eng-Huat ;

Tanaka, Hiroshi ;

We, Yi-Long ;

Yang, James C-H ;

Zhang, Li ;

Zhou, Caicun ;

Maerten, Angela ;

Tang, Wenbo ;

Yamamoto, Nobuyuki .

LUNG CANCER, 2019, 132 :126-131

← 1 2 3 4 5 →